The U.S. House Appropriations Committee says HRSA should use "any available means" to hold drug makers accountable for curtailing "use of 340B drugs in contract pharmacies."

House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials

The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report